Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of radiolabeled galeterone in healthy males
NCT02729376Phase 1Completed
- Sponsor
- LTN Pharmaceuticals, Inc.
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galeterone in prostate cancer (PCa), sponsored by LTN Pharmaceuticals, Inc. Primary endpoints: Radioactivity concentration equivalents in plasma at 168 hours, Single dose galeterone concentrations in plasma at 168 hours and 3 more. Started Mar 2016; status: completed.
02
Drugs
galeterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02729376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729376.